alrizomadlin
alrizomadlin: 3 clinical trials tracked.
alrizomadlin evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about alrizomadlin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (3)
Early Phase Study to Evaluate the MEK Inhibitor Selumetinib With the MDM2 Inhibitor APG-115 in Patients With Neurofibromatosis Type 1 and Pre-malignant and Malignant Peripheral Nerve Sheath Tumors
Primary endpoint: The number of treated patients with adverse events as determined by the common criteria for adverse version 5 (CTCAEv5).
A Phase Ib-ⅡClinical Study of APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
Primary endpoint: Dose Limiting Toxicity (Phase I)
A Phase IIa Study Evaluating the Pharmacokinetics, Safety and Efficacy of APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With Relapsed/Refractory T-Cell Prolymphocytic Leukemia (R/R T-PLL) or Non-Hodgkin's Lymphoma (NHL).
Primary endpoint: Maximum tolerated dose of APG-115